About this trial
What is this study about? This study is comparing two ways of giving surfactant, a medicine that helps premature infants breathe better. Surfactant can be given using a thin tube ("Less Invasive Surfactant Administration", called the LISA method) or through a small airway device placed in the baby's throat above the vocal cords ("Surfactant Administration through Laryngeal or Supraglottic Airway", called the SALSA method). The goal is to see which method is safer and more effective for preterm infants who are born at 29-36 weeks of pregnancy and have trouble breathing.
What is the main question (hypothesis)? Infants who receive surfactant using the SALSA method will have fewer heart rate and breathing-related problems than those who receive it using the LISA method.
What are the aims? Aim 1: Are babies in the SALSA group less likely to have low heart rate or low oxygen levels during the procedure compared to babies in the LISA group? Aim 2: Do fewer babies in the SALSA group need to be put on a breathing machine within the first 72 hours of life? Aim 3: Does the SALSA method help reduce the overall time babies need breathing support and lower the cost of their care in the NICU?
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All preterm infants born between 29-36 weeks' gestation.
Infants with birthweight greater than or equal to 750 grams and admitted to the NICU on CPAP for respiratory support requiring at least FiO2 25% and qualify for LISA procedure
Disqualifiers
Infants who require intubation prior to surfactant therapy
Infants with known severe congenital anomalies (complex congenital heart disease, airway and central nervous system anomalies)
Infants whose birth weight is less than 750 grams or oropharynx unable to accommodate laryngeal mask airways
Trial design
Parallel
Treatments tested in this trial
Surfactant Administration through Laryngeal or Supraglottic Airway
Procedure/SurgerySurfactant Administration through Supraglottic Airway Devices -AerVia sizes S, M, L, XL
Surfactant Administration through Thin Catheter
Procedure/SurgeryThin Catheter
Treatment groups
Trial outcomes
Primary outcomes
Combined bradycardia (heart rate < 100 for > 10 seconds) and hypoxemia (SpO2 < 80% for > 30 seconds) during surfactant administration
* Bradycardia: defined as heart rate \< 100 beats per minute for \> 10 seconds. Heart rate will be obtained from participant's heart rate monitor. * Hypoxemia: oxygen saturation (SpO2) =\< 80% for \> 30 seconds. Oxygen saturation will be obtained from participant's pulse oximeter monitor * Events will be recorded by bedside respiratory therapy and/or bedside nurse during the procedure
Secondary outcomes
Procedural success rate on first attempt
* Procedure attempt is defined at the introduction of laryngoscope blade into mouth for LISA, supraglottic airway for SALSA. * Procedural success is defined by the ability to insert catheter or laryngeal mask airway and administer surfactant with less than 25% of surfactant aspirated from the stomach post administration * Rate will be calculated as a percentage of participants in each arm
Intubation rate
* Rate will be calculated as a percentage of participants in each arm Invasive mechanical ventilation within first 72 hours of life after surfactant * Participants' need for and timing of intubation will be obtained from electronic medical record
Mean number of attempts required
Procedure attempt will be defined as introduction of laryngoscope blade into mouth for LISA and introduction of supraglottic airway into mouth for SALSA.
Total duration of CPAP and mechanical ventilation days
Total numbers of days on continuous end positive expiratory pressure (CPAP) and invasive mechanical ventilation
Sponsors and contacts
Click on the lead sponsor to view all of their trials.